A leader and respected voice in the telemedicine field, Dr. Peter “Pete” Killcommons founded Medweb in 1992 and has visited more than 50 countries in his work. Outside of his professional life, Dr. Peter Killcommons remains connected to the medical field through membership in the American Medical Association.
Insurance Providers Evolving to Accommodate Telemedicine CoveragePeter Killcommons
An alumnus of New York Medical College, Dr. Peter "Pete" Killcommons founded Medweb in 1992 and continues to serve as the company's CEO. In this capacity, Peter Killcommons oversees multiple divisions, including disaster response and telemedicine.
ComPsych® Corporation has released a major report that analyzes gender, age and industry differences in millions of EAP/work-life calls over a 12-month period. Get the full report at www.compsych.com/resources.
This presentation was created by SS/A Kevin Cashman
Maine Drug Enforcement Agency, Cumberland District Task Force for the 11/29/10 CADCA town hall meeting.
Dr. Arnie Milstein: Is Employee Health Insurance Failing Americans?reportingonhealth
Dr. Arnold Milstein's slides from the Center for Health Journalism webinar, "Is Employee Health Insurance Failing Americans?" 7.23.19
More info: https://www.centerforhealthjournalism.org/content/employee-health-insurance-failing-americans
Katherine Hempstead: "Left in Limbo: Obamacare’s Shaky Insurance Exchanges" 6...reportingonhealth
Katherine Hempstead's slides from the Center for Health Journalism webinar, "Left in Limbo: Obamacare’s Shaky Insurance Exchanges," 6.7.17
More info: https://www.centerforhealthjournalism.org/content/left-limbo-obamacares-shaky-insurance-exchanges
Kathleen Nolan: "Medicaid Undone? Covering the Safety Net’s New Future" 7.26.17reportingonhealth
Kathleen Nolan's slides from the Center for Health Journalism webinar, "Medicaid Undone? Covering the Safety Net’s New Future," 7.26.17
More info: https://www.centerforhealthjournalism.org/content/medicaid-undone-covering-safety-nets-new-future
Seeking medical attention for chronic pain is often the primary reason behind prescribing opioids. The practice of prescribing opioid painkillers has been so rampant that it led to an epidemic, which the United States has been struggling with for decades. Although medical practices, guidelines and recommendations explicitly point out that prescribing opioid pain pills should always outweigh the risks, they continue to wreak havoc across the North American continent.
Opioid Epidemic - Causes, Impact and FutureCitiusTech
In 2017, everyday, more than 130 people died in the US after overdosing on opioids. This document talks about America's worst drug crisis ever and shares how technology can play a role to cope up with this epidemic.
Insurance Providers Evolving to Accommodate Telemedicine CoveragePeter Killcommons
An alumnus of New York Medical College, Dr. Peter "Pete" Killcommons founded Medweb in 1992 and continues to serve as the company's CEO. In this capacity, Peter Killcommons oversees multiple divisions, including disaster response and telemedicine.
ComPsych® Corporation has released a major report that analyzes gender, age and industry differences in millions of EAP/work-life calls over a 12-month period. Get the full report at www.compsych.com/resources.
This presentation was created by SS/A Kevin Cashman
Maine Drug Enforcement Agency, Cumberland District Task Force for the 11/29/10 CADCA town hall meeting.
Dr. Arnie Milstein: Is Employee Health Insurance Failing Americans?reportingonhealth
Dr. Arnold Milstein's slides from the Center for Health Journalism webinar, "Is Employee Health Insurance Failing Americans?" 7.23.19
More info: https://www.centerforhealthjournalism.org/content/employee-health-insurance-failing-americans
Katherine Hempstead: "Left in Limbo: Obamacare’s Shaky Insurance Exchanges" 6...reportingonhealth
Katherine Hempstead's slides from the Center for Health Journalism webinar, "Left in Limbo: Obamacare’s Shaky Insurance Exchanges," 6.7.17
More info: https://www.centerforhealthjournalism.org/content/left-limbo-obamacares-shaky-insurance-exchanges
Kathleen Nolan: "Medicaid Undone? Covering the Safety Net’s New Future" 7.26.17reportingonhealth
Kathleen Nolan's slides from the Center for Health Journalism webinar, "Medicaid Undone? Covering the Safety Net’s New Future," 7.26.17
More info: https://www.centerforhealthjournalism.org/content/medicaid-undone-covering-safety-nets-new-future
Seeking medical attention for chronic pain is often the primary reason behind prescribing opioids. The practice of prescribing opioid painkillers has been so rampant that it led to an epidemic, which the United States has been struggling with for decades. Although medical practices, guidelines and recommendations explicitly point out that prescribing opioid pain pills should always outweigh the risks, they continue to wreak havoc across the North American continent.
Opioid Epidemic - Causes, Impact and FutureCitiusTech
In 2017, everyday, more than 130 people died in the US after overdosing on opioids. This document talks about America's worst drug crisis ever and shares how technology can play a role to cope up with this epidemic.
Running head OPIOID CRISIS PUBLIC POLICY PAPER .docxglendar3
Running head: OPIOID CRISIS PUBLIC POLICY PAPER 1
OPIOID CRISIS PUBLIC POLICY PAPER 7
Opioid Crisis Public Policy Paper
Anniesha Overton
Strayer Umiversity
Summary of the policy
The opioid crisis has been a significant public health concern in the United States since the late 1990s. The inability to develop strategic legislation and regulation to control the use of opioid has been critical to the development of the opioid crisis. The opioid crisis involves the use of both prescription and non-prescription opioid drugs. According to the Center for Disease control and prevention, the rate of opioid addiction has been significantly increasing over the years. From 1999 to 2016, at least 350,000 individuals have died from related opioid addiction, which includes prescription and illicit opioids.
Unlicensed pharmacies and overdependence on these drugs in pain management have been major concepts, which have created a challenging setting where the abuse of prescription drugs can be controlled. The underlying basis of this problem is the current assumption in the United States that medical practitioners can cure almost everything. Even though it is essential to understand that prescription drugs are effective in pain management, the drugs are required to be offered based on the prescriptions issued (McDonald & Lambert, 2016). It is also noted that they should not be used regularly since they created a very detrimental habit to patient wellbeing because they have addictive properties, which make it dangerous when consumed in large portions.
Confronting opioid addiction requires significant efforts by all stakeholders in healthcare in ensuring that there is a common objective in providing that there is a crucial focus in integrating quality focus in preventing opioid addiction. Considering the fact that a prescribed drug mainly propagates opioid addiction. It is essential to ensure that they are issued through consideration of critical healthcare knowledge regarding the admissibility of opioid drugs (Bihel, 2016). Nurses have a significant role to play regarding the overall development of the opioid addiction crisis. Critical issues that have been identified in opioid drug abuse include improper use, lack of the required knowledge and related interpretation in the use of opioid prescribed drugs and decreased regulation and legislation from the government regarding the existing concern on the increasing addiction levels across the country.
Players
The increase in opioid crisis has had a direct and indirect influence on different stakeholders. Therefore developing a strong focus on essential strategies that can help limit the overall impact of the opioid crisis on the lives of an individual is critical. The national institute on drug abuse reported that in 2015, 33,091 deaths were reported be.
Running head OPIOID CRISIS PUBLIC POLICY PAPER .docxtodd581
Running head: OPIOID CRISIS PUBLIC POLICY PAPER 1
OPIOID CRISIS PUBLIC POLICY PAPER 7
Opioid Crisis Public Policy Paper
Anniesha Overton
Strayer Umiversity
Summary of the policy
The opioid crisis has been a significant public health concern in the United States since the late 1990s. The inability to develop strategic legislation and regulation to control the use of opioid has been critical to the development of the opioid crisis. The opioid crisis involves the use of both prescription and non-prescription opioid drugs. According to the Center for Disease control and prevention, the rate of opioid addiction has been significantly increasing over the years. From 1999 to 2016, at least 350,000 individuals have died from related opioid addiction, which includes prescription and illicit opioids.
Unlicensed pharmacies and overdependence on these drugs in pain management have been major concepts, which have created a challenging setting where the abuse of prescription drugs can be controlled. The underlying basis of this problem is the current assumption in the United States that medical practitioners can cure almost everything. Even though it is essential to understand that prescription drugs are effective in pain management, the drugs are required to be offered based on the prescriptions issued (McDonald & Lambert, 2016). It is also noted that they should not be used regularly since they created a very detrimental habit to patient wellbeing because they have addictive properties, which make it dangerous when consumed in large portions.
Confronting opioid addiction requires significant efforts by all stakeholders in healthcare in ensuring that there is a common objective in providing that there is a crucial focus in integrating quality focus in preventing opioid addiction. Considering the fact that a prescribed drug mainly propagates opioid addiction. It is essential to ensure that they are issued through consideration of critical healthcare knowledge regarding the admissibility of opioid drugs (Bihel, 2016). Nurses have a significant role to play regarding the overall development of the opioid addiction crisis. Critical issues that have been identified in opioid drug abuse include improper use, lack of the required knowledge and related interpretation in the use of opioid prescribed drugs and decreased regulation and legislation from the government regarding the existing concern on the increasing addiction levels across the country.
Players
The increase in opioid crisis has had a direct and indirect influence on different stakeholders. Therefore developing a strong focus on essential strategies that can help limit the overall impact of the opioid crisis on the lives of an individual is critical. The national institute on drug abuse reported that in 2015, 33,091 deaths were reported be.
These slides are from on lecture on the role of psychotropic drugs in mental health treatment. Topics covered include the pharmaceutical industry, direct-to-consumer advertising, the CATIE and STAR*D studies, Medicare Part-D, and the role or pharmacy benefit managers.
washingtonpost.com
> Health
Correction to This Article
Previous versions of this article misspelled the name of Tito Fojo, of the National Cancer Institute. This version has been corrected.
Review of prostate cancer drug Provenge renews medical cost-benefit debate
TOOLBOX
Resize
PrintE-mailReprints
By Rob Stein
Washington Post Staff Writer
Monday, November 8, 2010; 7:52 AM
Federal officials are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.
The Centers for Medicare & Medicaid Services, which dictate what treatments the massive federal health-insurance program for the elderly will cover, is running a "national coverage analysis" of Provenge, the first vaccine approved for treating any cancer. The treatment costs $93,000 a patient and has been shown to extend patients' lives by about four months.
Although Medicare is not supposed to take cost into consideration when making such rulings, the decision to launch a formal examination has raised concerns among cancer experts, drug companies, lawmakers, prostate cancer patients and advocacy groups.
Provenge, which was approved for advanced prostate cancer in April, is the latest in a series of new high-priced cancer treatments that appear to eke out only a few more months of life, prompting alarm about their cost.
"This absolutely is the opening salvo in the drive to save money in the health-care system," said Skip Lockwood, who heads Zero - the Project to End Prostate Cancer, a Washington-based lobbying group. "If the cost wasn't a consideration, this wouldn't even be under discussion."
Those concerns have been heightened because the review comes after the bitter health-care reform debate, which was marked by accusations about rationing and "death panels." The appointment of Donald M. Berwick to head Medicare only intensified anxieties. President Obama sidestepped a Senate battle by naming Berwick, who has advocated for scrutinizing costs, when Congress was in recess in July.
Because men tend to be elderly when they get diagnoses of advanced prostate cancer, Medicare's decision will have a major effect on Provenge's availability. Regional Medicare providers paying for Provenge would have to stop. Private insurers also tend to follow Medicare's lead.
Medicare officials, who are convening a panel of outside advisers to vet the issue at a public hearing Nov. 17, say Provenge's price tag isn't an issue. But Berwick and other officials declined to discuss the rationale for the review.
"Certainly no one in the Medicare program would publicly state that the price tag would have anything to do with Medicare looking at it. But they are human beings, too. They notice things like that," said Sean Tunis, director of the Center for Medical Technology Policy and a former chief medical officer at Medicare. ...
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Multiple health problems in elderly peoplepage 950Ex.docxgilpinleeanna
Multiple health
problems in
elderly people
page 950
Excessive
drinking in
young women
page 952
Adverse drug
reactions in
elderly people
page 956
Palliative care
beyond cancer
page 958
Drug resistant
infections in
poor countries
page 948
Management
of chronic pain
page 954
M
A
K
IN
G
A
D
IF
FE
R
E
N
C
E
945BMJ | 26 APRIL 2008 | VOLUME 336
BMJ | Making a difference | 26 april 2008 | VoluMe 336 947
Running the gauntlet to improve
patient care
This supplement is the result of a gauntlet
thrown down, and picked up, during a dinner
in London just over a year ago. The gauntlet
thrower was Don Berwick, president of the
Institute for Healthcare Improvement in Boston.
What, he asked, was the BMJ Publishing Group
really for? What were we trying to achieve? In
reply, I and our chief executive, Stella Dutton,
were quick to quote the BMJ’s mission, which
ends with the crucial words “to improve
outcomes for patients.” Fine, said Don, but how
about being more specific: which outcomes,
what patients, by how much?
We took his suggestion seriously. Why not
target a few important healthcare problems,
taking a quality improvement approach
and focusing on the evidence on how to
make a difference in these areas? But how
to choose which issues to tackle among
the many millions of pressing healthcare
challenges facing the world? We turned in the
first instance to BMJ readers. In May 2007
we asked you to tell us what information was
most needed to improve the quality of care of
patients in clinical practice. From your many
rapid responses we harvested more than 200
ideas. After categorising these and matching
them against the priorities of national and
international bodies, we created a shortlist
of 12. With the help of an expert panel (see
http://makingadifference.bmj.com) we cut
these down to six.
Inevitably the choice of topics is subjective
rather than scientific, but the six we have
ended up with are interesting. Several turn the
spotlight on areas that are less than glamorous
and are perhaps all too often passed over, even
as their impact on individual lives and society
increases. Two topics deal with problems of
old age: multiple illness and adverse drug
reactions. Two deal with palliation: of chronic
pain and in dying from non-malignant disease.
The remaining topics deal with two very
different but serious and growing public health
challenges: drug resistant infections in the
developing world and excessive drinking in
young women. You will no doubt find important
gaps in what we have chosen. But if this
initiative proves useful we can expand it further.
On each of the six topics we’ve invited
leading commentators to write the pairs
of articles that make up this supplement.
One article in each pair aims to describe
the importance of the problem in terms of
its health and societal impact. The other
looks at the available evidence on quality
improvement initiat ...
Young Eagles Flights Program Enables Children to Experience FlyingPeter Killcommons
Dr. Peter Killcommons is the founder and CEO of Medweb, a company specializing in radiology, telemedicine, and disaster response. Throughout his career, Dr. Peter “Pete” Killcommons has participated in medical care trips and charity missions.
Telemedicine refers to the innovative means of distributing health-related services using digital devices such as phones and computers. As a result, patients could easily get medical advice, reminders, monitoring, education, etc., from the comfort of their homes. This technology also allows healthcare providers to evaluate, diagnose, and treat patients without needing an in-clinic session. Instead, patients can use medical apps or call a telemedicine number usually provided by the office of a primary care physician.
The development of telemedicine is deeply rooted in the growth of technology and society. Humans have long pursued relaying messages via optical telegraphy, telescope, and wireless transmission. The early forms of telemedicine performed with phones and radio have been generally supplemented with video telephony and advanced diagnostic methods and additional with telemedical devices. The 21st century has, however, seen telemedicine take a transformative role in healthcare through the emergence of high-speed portable internet devices.
Spurred by the 21st-century digital shift, virtual health sessions have become a vastly popular and ideal alternative to traditional in-clinic care. In its years of inception, unfamiliarity with the technology required to perform telemedicine services contributed heavily to its lack of widespread use and slow growth generally.
Cyber security has been a challenge for patients and healthcare providers using telemedicine platforms as the technology involves electronically transmitting patient data, making them susceptible to hackers and other security breaches. Healthcare organizations remain a big target for online criminals. There is also the issue of inadequate technical training and equipment for practitioners in this field.
Dr. Peter “Pete” Killcommons completed his MD at the New York Medical College in Valhalla, New York. An ardent advocate of telemedicine, Dr. Peter Killcommons is a member of the American Telemedicine Association (ATA). ATA promotes virtual care to enable patients to get the best healthcare possible.
Convenience is a key benefit a patient gets from virtual care. Virtual visits allow patients to consult with their caregivers without traveling to and from a hospital, clinic, or other healthcare institution.
But this is not just about convenience. According to the National Rural Health Association, the ratio of patients to primary care physicians in rural areas is fewer than 40 doctors for every 100,000 people, in comparison to 53 physicians for every 100,000 patients in urban areas. Virtual care in these regions provides access to caregivers that patients would not otherwise have.
Beyond primary care, virtual care gives patients access to specialists who may be even farther away - not only in rural locations but also in small towns and suburbs. According to Harvard Health, patients may also save money with virtual treatment, which typically costs just $40 to $50 for each appointment.
As the founder and CEO of Medweb, Dr. Peter Killcommons is responsible for the medical software company’s divisions of radiology and telemedicine. Dr. Peter (Pete) Killcommons invented web-based radiology viewers, making him a pioneer of teleradiology technology. Dr. Killcommons is a member of the American Medical Association (AMA).
The AMA holds an annual scientific conference on physician health. The 2021 American Conference on Physician Health (ACPH) is organized in collaboration with Mayo Clinic and Stanford University. The three-day event will be held at Hyatt Regency Scottsdale Resort and Spa on October 7, 2021.
This year’s ACPH tackles the theme of promoting physician well-being through health system change. Discussions and workshops will address the role of healthcare infrastructure and organizational responsibility toward physician health.
Interested individuals can submit their abstracts in two categories: research or workshop. The former category comprises posters and oral presentations while the latter includes interactive sessions. Registration for the conference opens in summer 2021.
Survey Finds Mental Health Patients Most Interested in TelemedicinePeter Killcommons
Experienced telemedicine professional Peter "Pete" Killcommons serves as the CEO of Medweb, a medical software and device company. Peter Killcommons also runs Medweb’s telemedicine division.
ATA Makes Recommendations for Special Telehealth DEA RegistrationPeter Killcommons
An executive who has worked to promote telemedicine in Japan, the Cape Verde Islands, and other locations worldwide, Dr. Peter (Pete) Killcommons serves as the CEO of Medweb, a medical device and software firm based in San Francisco. Additionally, Dr. Peter Killcommons is a member of the American Telemedicine Association (ATA).
Laughs for the Troops Treats Trauma with Family-Friendly HumorPeter Killcommons
As the CEO of Medweb, Dr. Peter “Pete” Killcommons manages the company’s operations, including the radiology, telemedicine, and disaster response divisions. In addition, Dr. Peter Killcommons is committed to supporting a variety of nonprofit organizations, including Laughs for the Troops.
Cabo Verde Islands in Africa Feature Integrated Telemedicine NetworkPeter Killcommons
The CEO of Medweb in San Francisco, Peter “Pete” Killcommons, MD, manages a prominent medical software and device company. Credited with inventing web-based radiology viewers, Dr. Peter Killcommons regularly travels to expand the use of telemedicine, making a 2018 trip to Cabo Verde, Africa, to assist with implementation.
Accomplished healthcare administration executive Dr. Peter ‘Pete’ Killcommons founded the telemedicine firm MedWeb in 1992. Under Dr. Peter Killcommons direction, MedWeb has developed proprietary and state of the art technical solutions to administering patient care, including teleradiology products and the web portal e-Visit.
CNN Travel Names EAA Museum a Top 20 Aviation Museum in the WorldPeter Killcommons
With more than 25 years of experience, Peter "Pete" Killcommons serves as the chief executive officer of Medweb. Over his career, Peter Killcommons has provided medical care in remote and dangerous areas, including serving as a volunteer pilot for disaster response. To complement his professional pursuits, he is a member of the Experimental Aircraft Association.
For more than 25 years, Peter “Pete” Killcommons, MD, has served as founder and chief executive of Medweb, a company that specializes in telemedicine services such as live stream consulting. Active in the field of telemedicine, Peter Killcommons is a longtime member of the American Telemedicine Association (ATA).
Dr. Peter “Pete” Killcommons balances a busy career as a medical technology executive with a commitment to a range of philanthropic initiatives, including the Fisher House Foundation, Catholic Charities USA, and Rotary International. Professionally, Dr. Peter Killcommons leads Medweb, a San Francisco-based company in the telemedicine and medical technology sectors.
An alumnus of New York Medical College, Dr. Peter (“Pete”) Killcommons founded Medweb, which focuses on providing telemedicine services to developing countries. A keynote speaker at the First Armenian International Congress on Telemedicine and eHealth in 2011, Dr. Peter Killcommons engages with his profession through membership in the American Telemedicine Association (ATA).
A graduate of New York Medical College, Dr. Peter Killcommons has spent the past 25 years serving as the CEO of Medweb, a leading telemedicine platform. To stay at the forefront of industry trends, Peter Killcommons maintains membership in the American Telemedicine Association (ATA).
Fisher House Foundation Prepares to Host 15th Annual Golf ClassicPeter Killcommons
For more than 25 years, Dr. Peter “Pete” Killcommons has served as CEO of Medweb in San Francisco. Under his guidance, the company provides web-enabled telemedicine solutions for organizations around the globe. Alongside his work as a physician and business leader, Dr. Peter Killcommons gives back to the community through his support of several nonprofit groups, including Fisher House Foundation.
Medweb Provides Disaster Relief Internationally and at HomePeter Killcommons
As founder and CEO of Medweb in San Francisco, Peter “Pete” Killcommons guides his company in providing telemedicine and imaging services; his firm is one of the few corporations that include a dedicated philanthropic division. Among the recipients of Peter Killcommons’ charity projects are disaster sites in the United States and abroad.
In 1992, Dr. Peter Killcommons founded Medweb. The company provides medical imaging and telemedicine services to patients around the globe. Medweb's offerings include a disaster response division, radiology, and telemedicine. Additionally, Medweb hosts an extensive array of philanthropic programs. Dr. Pete Killcommons complements Medweb's charitable work through affiliations with organizations such as American Red Cross and Fisher House.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
2. Introduction
• A leader and respected voice in the telemedicine field, Dr. Peter
“Pete” Killcommons founded Medweb in 1992 and has visited more
than 50 countries in his work. Outside of his professional life, Dr.
Peter Killcommons remains connected to the medical field through
membership in the American MedicalAssociation.
The AMA recently commented on statistics that show opioid
prescriptions went down by 22 percent between the years of 2013
and 2017.The organization points to this trend as proof that the
healthcare community is becoming more aware of the problems
that opioid dependence can cause.
3. American Medical Association
• Even with the decrease in prescriptions, however, the number of
deaths related to opioids such as fentanyl and heroin are still
increasing, which means that prescription control alone isn’t
enough to solve the problem.The AMA says it will take a combined
effort from all key stakeholders (lawmakers, healthcare facilities,
insurers, etc.) to form a comprehensive strategy for better, non-
opioid based pain management and treatment for those caught in
the cycle of addiction in order to start seeing more significant
results.